Vanguard Global Advisers
LAB icon

Vanguard Global Advisers’s Standard BioTools LAB Stock Holding History

Vanguard Global Advisers’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Hold
129,323
– – ﹤0.01% 2750
2026
Q1 		$119K Buy
+129,323
New +$157K ﹤0.01% 2657

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Global Advisers's LAB Position: Q2 2026 in Review

Vanguard Global Advisers held its Standard BioTools (LAB) position steady in Q2 2026 at 129,323 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

Vanguard Global Advisers first reported a position in LAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $119K in Q1 2026. 141 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Vanguard Global Advisers held 129,323 shares of Standard BioTools worth $106K as of Q2 2026.
  • Vanguard Global Advisers left its Standard BioTools share count unchanged in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2750 holding.
  • Vanguard Global Advisers first reported a position in Standard BioTools in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Standard BioTools position peaked at $119K in Q1 2026.
  • 141 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.